CDKN2A and melanoma: This discrepancy may be explained by differences in perceived disease severity, as most CDKN2A PV carriers had survived melanoma, in contrast to the BRCA1 cohort, where a large percentage of affected relatives in the BRCA1 cohort had died of their disease [21].